News

Biognosys Launches New Plasma Proteomics Solution P2-iST and OmicsFlow Platform, and Announces the Formation of Biognosys Group

November 10, 2025 – TORONTO, Canada. Biognosys Group, a global leader in mass spectrometry-based multiomics solutions, today announced the launch of the P2-iST Plasma solution and OmicsFlow® platform at the HUPO World Conference, taking place November 9–13 in Toronto, Canada. Formation of the Biognosys Group  Biognosys has become part of the newly established Biognosys...

read more

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the...

read more

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

INGELHEIM, Germany and ZURICH, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim and CDR-Life, Inc. today announced a new global licensing agreement to develop CDR-Life’s unique antibody-based molecule CDR111 for autoimmune diseases. CDR111 is a trispecific M-gager®, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. “Our...

read more

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...

read more